ACC 2015: AstraZeneca optimistic on Brilinta after PEGASUS, others less so
This article was originally published in Scrip
Executive Summary
AstraZeneca's US president Paul Hudson is optimistic about the opportunities for Brilinta (ticagrelor) in longer-term treatment of acute coronary syndrome (ACS) based on results from the Phase III PEGASUS clinical trial, but analysts and doctors are concerned about the bleeding risk associated with the drug.
You may also be interested in...
AstraZeneca Groomed Paul Hudson For His New Role … At Novartis
Ten years at AstraZeneca PLC have prepared US President and Executive Vice President of North America Paul Hudson for his next C-suite job, but unfortunately for his current employer that gig is with a major competitor – Novartis AG.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.